Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$15.36
$0.16(1.28%)
At close: 4:00 PM EDT
$15.36
$0.16(1.28%)
Day’s Range― - ―
52-Week Range$6.27 - $27.40
Previous CloseN/A
Volume4.70K
Average Volume (3M)36.47K
Market Cap
$72.55M
Enterprise Value$66.85M
Total Cash (Recent Filing)$53.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 18, 2026EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.89
Shares Outstanding8,967,693
10 Day Avg. Volume24,517
30 Day Avg. Volume36,471
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$43.00Price Target Upside179.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-5.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-free balance sheet reduces near-term solvency pressure and avoids mandatory interest payments while PMN advances its pipeline. This gives management greater flexibility to direct available capital toward research and clinical development, although it does not remove the need for future financing.
PMN310 Safety ProfileThe interim safety profile is a potentially important differentiator for PMN310 because ARIA risk is a stated limitation of existing plaque-binding antibodies. If maintained in longer follow-up, favorable tolerability could support development and adoption in a broader Alzheimer’s population.
Biomarker ResponseEarly reductions in multiple Alzheimer’s biomarkers provide supportive evidence that PMN310 is affecting disease-relevant biology rather than only producing a safety signal. This strengthens the clinical rationale and may improve the probability of continued development, while clinical efficacy remains unproven.
Bears Say
No Commercial RevenuePMN remains pre-commercial, so its operating model has not yet demonstrated product demand or recurring revenue generation. Continued losses without a revenue base leave future progress dependent on successful clinical development and external financing rather than internally funded operations.
Persistent Cash BurnPersistent negative cash flow indicates that research and operations are consuming capital faster than the business generates it. Unless cash generation improves or development milestones attract funding, ongoing burn can require additional financing and create potential dilution for existing shareholders.
Unproven Clinical EfficacyThe current PMN310 evidence is limited to interim safety and biomarker observations, so it has not yet shown that treatment improves clinical outcomes. The next development phase therefore remains exposed to efficacy uncertainty, which could materially affect the pipeline’s value and funding prospects.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $27.40 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $72.55M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Aug 13, 2026. The company reported -$1.28 earnings per share for the quarter, beating the consensus estimate of -$1.379 by $0.099.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.25.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$1.28 in its last earnings report, beating expectations of -$1.379. Following the earnings report the stock price went up 0.473%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (179.95% Upside)
$43.00 (179.95% Upside)
Blogger Sentiment
Bullish
PMN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 46.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.06%
12-Months-Change
Fundamentals
Return on Equity
-143.09%
Trailing 12-Months
Asset Growth
496.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Earnings Call
Q2 2026
0:00 / 0:00
PMN Stock 12 Month Forecast
Average Price Target
$43.00
▲(179.95% Upside)
Technical Analysis
Ownership Overview
13.43% Insiders
<0.01% Mutual Funds
45.60% Other Institutional Investors
40.97% Public Companies and
Individual Investors